Amoxicillin plus temocillin as an alternative empiric therapy for the treatment of severe hospital-acquired pneumonia: results from a retrospective audit

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 34, Issue 8, 2015, Pages 1693-1699

  Habayeb, H ^a   Sajin, B ^a   Patel, K ^a   Grundy, C ^a   Al Dujaili, A ^b   Van de Velde, S ^c  

^a ASHFORD AND ST PETER'S HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^c Eumedica SA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; PIPERACILLIN PLUS TAZOBACTAM; TEMOCILLIN; ANTIINFECTIVE AGENT; PENICILLIN DERIVATIVE;

ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; KIDNEY FAILURE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; ADULT; ADVERSE DRUG REACTION; CHEMICALLY INDUCED; CROSS INFECTION; HOSPITAL; MIDDLE AGED; PNEUMONIA; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DIARRHEA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HOSPITALS; HUMANS; MALE; MIDDLE AGED; PENICILLINS; PNEUMONIA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84937970521     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-015-2406-x     Document Type: Article

References (31)

1. Lai CC, Wang CY, Chu CC, Tan CK, Lu CL, Lee YC, Huang YT, Lee PI, Hsueh PR (2011) Correlation between antibiotic consumption and resistance of Gram-negative bacteria causing healthcare-associated infections at a university hospital in Taiwan from 2000 to 2009. J Antimicrob Chemother 66:1374–1382
2. Harris AD, Perencevich E, Roghmann MC, Morris G, Kaye KS, Johnson JA (2002) Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother 46:854–858
3. McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M, Scheetz MH (2013) Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae. Antimicrob Agents Chemother 57:5131–5133
4. Appelbaum PC (2012) 2012 and beyond: potential for the start of a second pre-antibiotic era? J Antimicrob Chemother 67:2062–2068
5. Livermore DM (2009) Has the era of untreatable infections arrived? J Antimicrob Chemother 64:i29–i36
6. Livermore DM, Tulkens PM (2009) Temocillin revived. J Antimicrob Chemother 63:243–245
7. Balakrishnan I, Awad-El-Kariem FM, Aali A, Kumari P, Mulla R, Tan B, Brudney D, Ladenheim D, Ghazy A, Khan I, Virgincar N, Iyer S, Carryn S, Van de Velde S (2011) Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC {beta}-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 66:2628–2631
8. Rodriguez-Villalobos H, Bogaerts P, Berhin C, Bauraing C, Deplano A, Montesinos I, de Mendonca R, Jans B, Glupczynski Y (2011) Trends in production of extended-spectrum beta-lactamases among Enterobacteriaceae of clinical interest: results of a nationwide survey in Belgian hospitals. J Antimicrob Chemother 66:37–47
9. Livermore DM, Hope R, Fagan EJ, Warner M, Woodford N, Potz N (2006) Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J Antimicrob Chemother 57:1012–1014
10. Woodford N, Pike R, Meunier D, Loy R, Hill R, Hopkins KL (2014) In vitro activity of temocillin against multidrug-resistant clinical isolates of Escherichia coli, Klebsiella spp. and Enterobacter spp., and evaluation of high-level temocillin resistance as a diagnostic marker for OXA-48 carbapenemase. J Antimicrob Chemother 69:564–567
11. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58:377–382
12. Wren MWD, Kinson R, Sivapalan M, Shemko M, Shetty NR (2009) Detection of Clostridium difficile infection: a suggested laboratory diagnostic algorithm. Br J Biomed Sci 66:175–179
13. Rahme C, Butterfield JM, Nicasio AM, Lodise TP (2014) Dual beta-lactam therapy for serious Gram-negative infections: is it time to revisit? Diagn Microbiol Infect Dis 80:239–259
14. Verbist L, Verhaegen J (1984) Effect of temocillin in combination with other beta-lactam antibiotics. Antimicrob Agents Chemother 25:142–144
15. Bow EJ, Rotstein C, Noskin GA, Laverdiere M, Schwarer AP, Segal BH, Seymour JF, Szer J, Sanche S (2006) A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 43:447–459
16. Karino F, Miura K, Fuchita H, Koba N, Nishikawa E, Hotta T, Okimoto T, Iwamoto S, Tsubata Y, Tada M, Hamaguchi S, Honda T, Ohe M, Sutani A, Kuraki T, Takeyama H, Isobe T (2013) Efficacy and safety of piperacillin/tazobactam versus biapenem in late elderly patients with nursing- and healthcare-associated pneumonia. J Infect Chemother 19:909–915
17. Baines SD, Freeman J, Wilcox MH (2005) Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J Antimicrob Chemother 55:974–982
18. Wilcox MH, Freeman J, Fawley W, MacKinlay S, Brown A, Donaldson K, Corrado O (2004) Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother 54:168–172
19. Alston WK, Ahern JW (2004) Increase in the rate of nosocomial Clostridium difficile-associated diarrhoea during shortages of piperacillin-tazobactam and piperacillin. J Antimicrob Chemother 53:549–550
20. Mendez MN, Gibbs L, Jacobs RA, McCulloch CE, Winston L, Guglielmo BJ (2006) Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections. Pharmacotherapy 26:61–67
21. Shah K, Pass LA, Cox M, Lanham M, Arnold FW (2012) Evaluating contemporary antibiotics as a risk factor for Clostridium difficile infection in surgical trauma patients. J Trauma Acute Care Surg 72:691–695
22. Balassiano IT, Dos Santos-Filho J, de Oliveira MP, Ramos MC, Japiassu AM, Dos Reis AM, Brazier JS, de Oliveira FE, Domingues RM (2010) An outbreak case of Clostridium difficile-associated diarrhea among elderly inpatients of an intensive care unit of a tertiary hospital in Rio de Janeiro, Brazil. Diagn Microbiol Infect Dis 68:449–455
23. Vernaz N, Hill K, Leggeat S, Nathwani D, Philips G, Bonnabry P, Davey P (2009) Temporal effects of antibiotic use and Clostridium difficile infections. J Antimicrob Chemother 63:1272–1275
24. Settle CD, Wilcox MH, Fawley WN, Corrado OJ, Hawkey PM (1998) Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment Pharmacol Ther 12:1217–1223
25. Yeung E, Gore JG, Auersperg EV (2012) A retrospective analysis of the incidence of clostridium difficile associated diarrhea with meropenem and piperacillin-tazobactam. Int J Collab Res Intern Med Public Health 4:1567–1576
26. Slimings C, Riley TV (2014) Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 69:881–891
27. Goldstein EJC (2011) Beyond the target pathogen: ecological effects of the hospital formulary. Curr Opin Infect Dis 24(Suppl 1):S21–S31
28. Boon RJ, Beale AS (1985) Studies with temocillin in a hamster model of antibiotic-associated colitis. Antimicrob Agents Chemother 27:980–981
29. Mittermayer HW (1985) Influence of temocillin on human bowel flora. Drugs 29(Suppl 5):43–48
30. Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, Ramsay CR, Wiffen PJ, Wilcox M (2013) Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 4:CD003543
31. Song JY, Eun BW, Nahm MH (2013) Diagnosis of pneumococcal pneumonia: current pitfalls and the way forward. Infect Chemother 45:351–366